Medicines that have been provided to patients through the UK’s Early Access to Medicines Scheme (EAMS) are slightly more likely to secure a positive recommendation from the health technology assessment body, NICE, than products that were not part of the scheme, Pink Sheet analysis has revealed. NICE also issued final guidance faster for EAMS medicines.
The EAMS allows patients with life-threatening or seriously debilitating conditions to gain access to treatments in the UK before marketing authorization
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?